Evaluating an AI Tool for Detecting Thyrotoxic States

Condition(s) studied

Investigational drug(s) / intervention(s)

Heart rate-based AI software for detecting thyrotoxicosis: A software-based investigational medical device that uses artificial intelligence to detect the thyrotoxic state in patients with hyperthyroidism. The device analyzes resting heart rate data collected from wearable devices along with thyroid function test results (free T4 and TSH). The device is not FDA-approved and will be used solely for observational performance evaluation without influencing clinical care.

Study summary

This observational study aims to evaluate the performance of a software-based medical device, Glandy HYPER, in detecting the thyrotoxic state in patients with hyperthyroidism. The device utilizes heart rate data collected from commercially available wearable devices and compares it with thyroid function test results. The study will enroll patients diagnosed with Graves' disease, monitoring their heart rate during sleep and correlating these measurements with free T4 levels obtained through serial blood testing. No investigational device output will be disclosed to participants, and the study will not alter standard clinical care.

Eligibility

Primary outcome measure(s)

• F1 Score for Detection of Thyrotoxicosis Using the Investigational Software — At weeks 4, 8, and 12 after baseline (Visit 2), up to 12 weeks total
  The F1 score will be calculated to evaluate the performance of the AI-based investigational software in detecting thyrotoxic states. The device's output, derived from wearable heart rate data and reference data, will be compared against the diagnosis based on serum free T4 concentration at each time point. Each participant contributes multiple data pairs (evaluation-reference combinations) based on serial visits (V2-V5), and the F1 score will be calculated for each case and summarized across all cases.

Trial sites (1)

More THYROSCOPE INC. trials in the USA

Other trials for the same condition